Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, Randomised, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of 10 mg ZD4054 in Combination With Docetaxel in Comparison With Docetaxel in Patients With Metastatic Hormone-Resistant Prostate Cancer.

Next Previous
X
Search
Trial Profile

A Phase III, Randomised, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of 10 mg ZD4054 in Combination With Docetaxel in Comparison With Docetaxel in Patients With Metastatic Hormone-Resistant Prostate Cancer.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 01 Jul 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Zibotentan (Primary) ; Docetaxel
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms ENTHUSE-M1C
  • Sponsors AstraZeneca

    • Most Recent Events

    • 07 Jun 2022 Results (n=2028) from 4 randomized phase 3 trials (NCT00273338, NCT00988208, NCT00617669, and NCT00519285) presented at the 58th Annual Meeting of the American Society of Clinical Oncology
    • 10 Apr 2021 Data from the comparator arm of this phase III clinical trial for metastatic hormone-resistant prostate cancer study used to show a model which captures the rebound above baseline in neutrophil count seen in docetaxel patients presented at the 112th Annual Meeting of the American Association for Cancer Research
    • 21 Sep 2020 Results presented at the 45th European Society for Medical Oncology Congress

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top